Boncz I et al. Irányított Betegellátási Modell (IBM): a fejkvótaszámítás szerepe és módszertana.. (2003) IME: INTERDISZCIPLINÁRIS MAGYAR EGÉSZSÉGÜGY / INFORMATIKA ÉS MENEDZSMENT AZ EGÉSZSÉGÜGYBEN 1588-6387 1789-9974 2 6 19-22,
1367323
Szakcikk (Folyóiratcikk) | Tudományos[1367323]
Móczár C. et al. Hungarian Managed Care initiatives between 2000 and 2007: Regional health outcomes of the Hungarian Care Organizations. (2019) PRIMARY HEALTH CARE RESEARCH AND DEVELOPMENT 1463-4236 1477-1128 20
Dankó D et al. Félsiker vagy „félkudarc” ? A magyar Irányított Betegellátási Rendszer tapasztalatai a „Helyi IBR hálózatok teljesítményének értékelése” c. kutatás tükrében.. (2005)
Kornai János et al. Egyéni választás és szolidaritás: Az egyészségügy intézményi mechanizmusának reformja Kelet-Európában (Welfare, Choice and Solidarity in Transition: Reforming the Health Sector in Eastern Europe). (2004) ISBN:9631954641
Boncz I et al. Irányított Betegellátási Modell (IBM): a managed care helye a finanszírozási rendszerben, alapelvek és az Amerikai Egyesült Államok példája.. (2003) IME: INTERDISZCIPLINÁRIS MAGYAR EGÉSZSÉGÜGY / INFORMATIKA ÉS MENEDZSMENT AZ EGÉSZSÉGÜGYBEN 1588-6387 1789-9974 2 4 15-21,
1367402
Szakcikk (Folyóiratcikk) | Tudományos[1367402]
Dankó D et al. Félsiker vagy „félkudarc” ? A magyar Irányított Betegellátási Rendszer tapasztalatai a „Helyi IBR hálózatok teljesítményének értékelése” c. kutatás tükrében.. (2005)
Boncz Imre et al. Irányított Betegellátási Modell (IBM) II: managed care Nagy-Britanniában és az eszközrendszer elemei. (2003) IME: INTERDISZCIPLINÁRIS MAGYAR EGÉSZSÉGÜGY / INFORMATIKA ÉS MENEDZSMENT AZ EGÉSZSÉGÜGYBEN 1588-6387 1789-9974 2 5 10-13,
1671392
Szakcikk (Folyóiratcikk) | Tudományos[1671392]
Dankó D et al. Félsiker vagy „félkudarc” ? A magyar Irányított Betegellátási Rendszer tapasztalatai a „Helyi IBR hálózatok teljesítményének értékelése” c. kutatás tükrében.. (2005)
Csedo Z et al. Új modellek a modellben: Felső vezetői kihívások az irányított betegellátási modell tükrében. (2003) ORVOSI HETILAP 0030-6002 1788-6120 144 23 1135-1143,
1299151
Brennan A et al. The cost utility of Exelon Patch in the management of patients with Alzheimer’s disease in the UK.. (2007) VALUE IN HEALTH 1098-3015 1524-4733 10 6 p. A384,
3191149
Hyde Christopher et al. Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer's disease: systematic review and economic model. (2013) AGE AND AGEING 0002-0729 1468-2834 42 1 14-20
Bond M et al. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model. (2012) HEALTH TECHNOLOGY ASSESSMENT 1366-5278 16 21 1-+
Szalai Ákos et al. Versengő egészségbiztosítás megteremtése Magyarországon. (2007) KORMÁNYZÁS, KÖZPÉNZÜGYEK, SZABÁLYOZÁS 2 1 37-73,
1834761
Szakcikk (Folyóiratcikk) | Tudományos[1834761]
Király Lilla. Az egészségügyi ellátórendszer Kelet-közép Európában a szocialista és az azt követő időszakban, a magyar példán keresztül. (2015) JURA 1218-0793 21 2 63-75
Nagy Balázs et al. Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer's disease in the UK using MMSE- and ADL-based models.. (2011) INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY 0885-6230 26 5 483-494,
1491095
Szakcikk (Folyóiratcikk) | Tudományos[1491095]
Lipp Lindsey et al. In Vitro and in Vivo Optimization of Phase Sensitive Smart Polymer for Controlled Delivery of Rivastigmine for Treatment of Alzheimer's Disease. (2020) PHARMACEUTICAL RESEARCH 0724-8741 1573-904X 37 3
Steinbeisser Kathrin et al. Cost-effectiveness of a non-pharmacological treatment vs. "care as usual" in day care centers for community-dwelling older people with cognitive impairment: results from the German randomized controlled DeTaMAKS-trial. (2020) EUROPEAN JOURNAL OF HEALTH ECONOMICS 1618-7598 1618-7601 21 6 825-844
Pena-Longobardo L. M. et al. How relevant are social costs in economic evaluations? The case of Alzheimer's disease. (2019) EUROPEAN JOURNAL OF HEALTH ECONOMICS 1618-7598 1618-7601 20 8 1207-1236
Lin Pei-Jung et al. Family and Caregiver Spillover Effects in Cost-Utility Analyses of Alzheimer's Disease Interventions. (2019) PHARMACOECONOMICS 1170-7690 1179-2027 37 4 597-608
Flood Jessica et al. Caring for patients with dementia undergoing radiation therapy-A national audit. (2019) JOURNAL OF GERIATRIC ONCOLOGY 1879-4068 10 5 811-818
Ebrahem Anees Shajhan et al. A pharmacoeconomic evaluation of cholinesterase inhibitors and memantine for the treatment of Alzheimer's disease. (2018) EXPERT OPINION ON PHARMACOTHERAPY 1465-6566 1744-7666 19 11 1245-1259
Tong Thaison et al. Cost effectiveness of using cognitive screening tests for detecting dementia and mild cognitive impairment in primary care. (2017) INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY 0885-6230 32 12 1392-1400
Krol Marieke et al. Does Including Informal Care in Economic Evaluations Matter? A Systematic Review of Inclusion and Impact of Informal Care in Cost-Effectiveness Studies. (2015) PHARMACOECONOMICS 1170-7690 1179-2027 33 2 123-135
Sadowsky C.H. et al. Rivastigmine from capsules to patch: Therapeutic advances in the management of alzheimer’s disease and parkinson’s disease dementia. (2014) PRIMARY CARE COMPANION TO THE JOURNAL OF CLINICAL PSYCHIATRY 1523-5998 1555-211X 16 5
Mills Jonathan K et al. An assessment of the dementia CQUIN - an audit of improving compliance. (2014) DEMENTIA-INTERNATIONAL JOURNAL OF SOCIAL RESEARCH AND PRACTICE 1471-3012 1741-2684 13 5 697-703
Sonntag Michael et al. The Estimation of Utility Weights in Cost-Utility Analysis for Mental Disorders: A Systematic Review. (2013) PHARMACOECONOMICS 1170-7690 1179-2027 31 12 1131-1154
Gauthier Serge et al. Real-life effectiveness and tolerability of the rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease: the EMBRACE study. (2013) CURRENT MEDICAL RESEARCH AND OPINION 0300-7995 1473-4877 29 8 989-1000
Froestl Wolfgang et al. Cognitive Enhancers (Nootropics). Part 2: Drugs Interacting with Enzymes. (2013) JOURNAL OF ALZHEIMER'S DISEASE 1387-2877 1875-8908 33 3 547-658
Dhillon Sohita. Rivastigmine Transdermal Patch A Review of its Use in the Management of Dementia of the Alzheimer's Type. (2011) DRUGS 0012-6667 1179-1950 71 9 1209-1231
Nagy B et al. DEVELOPMENT OF A HEALTH ECONOMIC MODEL TO COMPARE THE PREVENTION, TREATMENT AND MANAGEMENT STRATEGIES OF TYPE 2 DIABETES. (2011) VALUE IN HEALTH 1098-3015 1524-4733 14 7 A486-A487,
2119466
Charokopou M et al. Methods applied in cost-effectiveness models for treatment strategies in type 2 diabetes mellitus and their use in Health Technology Assessments: a systematic review of the literature from 2008 to 2013. (2016) CURRENT MEDICAL RESEARCH AND OPINION 0300-7995 1473-4877 32 2 207-218
Mok Chiu Hang et al. Health State Utility Values for Type 2 Diabetes and Related Complications in East and Southeast Asia: A Systematic Review and Meta-Analysis. (2021) VALUE IN HEALTH 1098-3015 1524-4733 24 7 1059-1067
Nagy B et al. The cost-effectiveness of ulipristal acetate tablets in treating patients with moderate to severe symptoms of uterine fibroids. (2014) EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY 0301-2115 1872-7654 175 75-81,
2563507
Szakcikk (Folyóiratcikk) | Tudományos[2563507]
Smailova L.K. et al. Assessing the quality of life of patients with symptomatic uterine fibroid. (2020) Systematic Reviews in Pharmacy 0975-8453 11 2 176-182
Badiani Brigitta et al. Ulipristal acetate for pre-operative management of uterine fibroids: Modeling outcomes and costs. (2018) EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY 0301-2115 1872-7654 222 84-88
Singh Sukhbir S. et al. Re: The past, present, and future of selective progesterone receptor modulators in the management of uterine fibroids REPLY. (2018) AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY 0002-9378 1097-6868 219 4 425-426
Zakiyah N et al. Ulipristal acetate for pre-operative treatment of moderate-to-severe uterine fibroids in women of reproductive age in The Netherlands: cost minimization analysis and budget impact analysis. (2017) JOURNAL OF MEDICAL ECONOMICS 1369-6998 1941-837X 20 3 280-287
Ali Mohamed et al. Selective progesterone receptor modulators for fertility preservation in women with symptomatic uterine fibroids. (2017) BIOLOGY OF REPRODUCTION 0006-3363 1529-7268 97 3 337-352
Zaidieva YaZ et al. Treatment in patients with uterine myoma: Facts and unsolved problems: Лечение больных с миомой матки: факты и нерешенные вопросы. (2016) ROSSIISKII VESTNIK AKUSHERA-GINEKOLOGA 1726-6122 2309-5148 16 2 37-41
Wang Wei et al. Non-intervention observation: Dynamic evolution laws of inflammatory response in necrotizing enterocolitis. (2016) EXPERIMENTAL AND THERAPEUTIC MEDICINE 1792-0981 1792-1015 12 3 1770-1774
Tsoi B et al. Incorporating ulipristal acetate in the care of symptomatic uterine fibroids: A Canadian cost-utility analysis of pharmacotherapy management. (2015) CLINICOECONOMICS AND OUTCOMES RESEARCH 1178-6981 7 213-225
Ágh T et al. The Cost Effectiveness of Lisdexamfetamine Dimesylate for the Treatment of Binge Eating Disorder in the USA. (2016) CLINICAL DRUG INVESTIGATION 1173-2563 36 4 305-312,
3036747
Szakcikk (Folyóiratcikk) | Tudományos[3036747]
Berghoefer Anne et al. Descriptive Cost-Effectiveness Analysis of a Counseling and Coordination Model in Psychosocial Care. Integration of Health Care and Social Rehabilitation. (2020) FRONTIERS IN PSYCHIATRY 1664-0640 1664-0640 10
Ward Kristen et al. Lisdexamfetamine: chemistry, pharmacodynamics, pharmacokinetics, and clinical efficacy, safety, and tolerability in the treatment of binge eating disorder. (2018) EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY 1742-5255 1744-7607 14 2 229-238
Koenig Hans-Helmut et al. Economic evaluation of cognitive behavioral therapy and Internet-based guided self-help for binge-eating disorder. (2018) INTERNATIONAL JOURNAL OF EATING DISORDERS 0276-3478 1098-108X 51 2 155-164
Le Long Khanh-Dao et al. A systematic review of cost-effectiveness studies of prevention and treatment for eating disorders. (2018) AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY 0004-8674 1440-1614 52 4 328-338
Treasure Janet et al. Are trans diagnostic models of eating disorders fit for purpose? A consideration of the evidence for food addiction. (2018) EUROPEAN EATING DISORDERS REVIEW 1072-4133 1099-0968 26 2 83-91
Fornaro Michele et al. Lisdexamfetamine in the treatment of moderate-to-severe binge eating disorder in adults: systematic review and exploratory meta-analysis of publicly available placebo-controlled, randomized clinical trials. (2016) NEUROPSYCHIATRIC DISEASE AND TREATMENT 1176-6328 1178-2021 12 1827-1836
Nagy B et al. Cost-effectiveness of a risk based secondary screening program of type 2 diabetes. (2016) DIABETES-METABOLISM RESEARCH AND REVIEWS 1520-7552 1520-7560 32 7 710-729,
3036760
Szakcikk (Folyóiratcikk) | Tudományos[3036760]
Pöhlmann J. et al. Modeling Chronic Kidney Disease in Type 2 Diabetes Mellitus: A Systematic Literature Review of Models, Data Sources, and Derivation Cohorts. (2022) DIABETES THERAPY 1869-6953 1869-6961 13 4 651-677
Rurik Imre et al. Diabeteses betegek alapellátása Európában: Országok közötti összehasonlítás. (2022) DIABETOLOGIA HUNGARICA 1217-372X 2560-0168 30 3 181-188
van der Vliet et al. Ranking preventive interventions from different policy domains: What are the most cost-effective ways to improve public health?. (2020) INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH 1661-7827 1660-4601 17 6
Sugrue Daniel M. et al. Economic Modelling of Chronic Kidney Disease: A Systematic Literature Review to Inform Conceptual Model Design. (2019) PHARMACOECONOMICS 1170-7690 1179-2027
Ran X. et al. Recent Advances in the Economic Evidence Abroad of Early Detection and Treatment of Type 2 Diabetes:a Review from the Health Management Perspective. (2018) CHINESE GENERAL PRACTICE 1007-9572 21 34 4278-4282
Balazs Nagy et al. A conceptual framework for a long-term economic model for the treatment of attention-deficit/hyperactivity disorder. (2017) EXPERT REVIEW OF PHARMACOECONOMICS AND OUTCOMES RESEARCH 1473-7167 1744-8379 17 3 283-292,
3190474
Szakcikk (Folyóiratcikk) | Tudományos[3190474]
Dijk H.H. et al. Cost-Effectiveness and Cost Utility of Treatment of Attention-Deficit/Hyperactivity Disorder: A Systematic Review. (2021) JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY 1044-5463 1557-8992 31 9 578-596
Tesar Tomas et al. Cost-Utility Analysis of Heberprot-P as an Add-on Therapy to Good Wound Care for Patients in Slovakia with Advanced Diabetic Foot Ulcer. (2017) FRONTIERS IN PHARMACOLOGY 1663-9812 1663-9812 8,
3306713
Szakcikk (Folyóiratcikk) | Tudományos[3306713]
Quintero Diaz Esteban et al. Heberprot-p en el tratamiento del pie diabético. (2022) Revista Científica Arbitrada Multidisciplinaria PENTACIENCIAS 2806-5794 4 3 584-600
Rodríguez-Sánchez B. et al. Health economics of diabetic foot disease: Costs of diabetic neuropathy and diabetic foot. (2022) Megjelent: Diabetic Neuropathy pp. 211-221
Zamora Rodríguez M.L. et al. The categories of specialization in advanced technologies: An instrument to stimulate innovation in cuba. (2021) Universidad y Sociedad 2415-2897 2218-3620 13 5 200-212
Woods T.-J. et al. Economic evaluations considering costs and outcomes of diabetic foot ulcer infections: A systematic review. (2020) PLOS ONE 1932-6203 15 4
Vokó Zoltán et al. Az alacsony dózisú CT-vel végzett tüdőrákszűrés magyarországi egészség-gazdaságtani elemzésének koncepcionális terve [Model concept of the health economic evaluation of low-dose CT lung cancer screening in Hungary]. (2017) ORVOSI HETILAP 0030-6002 1788-6120 158 25 963-975,
3241530
Szakcikk (Folyóiratcikk) | Tudományos[3241530]
Zeng Chaoqiang et al. The application values of low dose spiral CT in screening of early lung cancer. (2019) XIANDAI ZHONGLIU YIXUE / JOURNAL OF MODERN ONCOLOGY 1672-4992 2019 2 297-300
Ottlakán A et al. Tüdőlebeny-eltávolítást követő kemoterápia tolerabilitását befolyásoló perioperatív tényezők [Perioperative factors influencing the tolerability of chemotherapy after lung lobe resection]. (2018) ORVOSI HETILAP 0030-6002 1788-6120 159 19 748-755
Nemeth B et al. A systematic review of health economic models and utility estimation methods in schizophrenia.. (2018) EXPERT REVIEW OF PHARMACOECONOMICS AND OUTCOMES RESEARCH 1473-7167 1744-8379 18 3 267-275,
3328102
Liang D. et al. Progress of the COVID-19: Persistence, Effectiveness, and Immune Escape of the Neutralizing Antibody in Convalescent Serum. (2022) PATHOGENS 2076-0817 11 12
Tan L. et al. Homologous recombination technology generated recombinant pseudorabies virus expressing EGFP facilitates to evaluate its susceptibility to different cells and screen antiviral compounds. (2022) RESEARCH IN VETERINARY SCIENCE 0034-5288 1532-2661 145 125-134
Wang Bing et al. Histamine Is Responsible for the Neuropathic Itch Induced by the Pseudorabies Virus Variant in a Mouse Model. (2022) VIRUSES 1999-4915 14 5
Hendriks L. et al. Cost-utility analysis of repetitive transcranial magnetic stimulation as add-on therapy to standard care for the treatment of hallucinations in schizophrenia. (2022) EUROPEAN PSYCHIATRY 0924-9338 1778-3585 65 1
Liu Q. et al. Antigenic Evolution Characteristics and Immunological Evaluation of H9N2 Avian Influenza Viruses from 1994–2019 in China. (2022) VIRUSES 1999-4915 14 4
Li X. et al. Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments (SMART-CAT) in first-episode schizophrenia patients: Rationale and trial design. (2021) SCHIZOPHRENIA RESEARCH 0920-9964 1573-2509 230 87-94
Buosi P. et al. Oxidative stress biomarkers in treatment-responsive and treatment-resistant schizophrenia patients. (2021) TRENDS IN PSYCHIATRY AND PSYCHOTHERAPY 2237-6089 2238-0019 43 4 278-285
Huang J. et al. Factor analysis of the relationship between PANSS score and family burden of patients with schizophrenia. (2021) BRAIN AND BEHAVIOR 2162-3279 2162-3279 11 8
Zhang L. et al. Antiviral effect of a bacteriophage on murine norovirus replication via modulation of the innate immune response. (2021) VIRUS RESEARCH 0168-1702 1872-7492 305
Jin Huajie et al. Systematic review of the methods of health economic models assessing antipsychotic medication for schizophrenia. (2020) PLOS ONE 1932-6203 1932-6203 15 7
Aceituno D. et al. Health State Utility Values in Schizophrenia: A Systematic Review and Meta-Analysis. (2020) VALUE IN HEALTH 1098-3015 1524-4733 23 9 1256-1267
Jin Huajie et al. A Systematic Review of Economic Models Across the Entire Schizophrenia Pathway. (2020) PHARMACOECONOMICS 1170-7690 1179-2027 38 6 537-555
Aceituno David et al. Health state utility values in schizophrenia: protocol for a systematic review and meta-analysis. (2019) EVIDENCE-BASED MENTAL HEALTH 1362-0347 1468-960X 22 4 142-144
Bogos Krisztina et al. Revising Incidence and Mortality of Lung Cancer in Central Europe: An Epidemiology Review From Hungary. (2019) FRONTIERS IN ONCOLOGY 2234-943X 2234-943X 9,
30866651
Szakcikk (Folyóiratcikk) | Tudományos[30866651]
Baum P. et al. Trends in age- and sex-specific lung cancer mortality in Europe and Northern America: Analysis of vital registration data from the WHO Mortality Database between 2000 and 2017. (2022) EUROPEAN JOURNAL OF CANCER 0959-8049 1879-2995 1879-0852 0014-2964 171 269-279
Elek Péter et al. Heterogeneous impact of the COVID-19 pandemic on lung, colorectal and breast cancer incidence in Hungary: results from time series and panel data models. (2022) BMJ OPEN 2044-6055 2044-6055 12 8
Salehiniya H. et al. Epidemiological Study of Lung Cancer in Iran: A Systematic Review. (2022) IRANIAN JOURNAL OF PUBLIC HEALTH 2251-6085 2251-6093 51 2 306-317
Wang J. et al. Characteristic of Molecular Subtypes in Lung Squamous Cell Carcinoma Based on Autophagy-Related Genes and Tumor Microenvironment Infiltration. (2022) JOURNAL OF ONCOLOGY 1687-8450 1687-8469 2022
Wéber András et al. A Központi Statisztikai Hivatal halálozási adatainak összevetése a Nemzeti Rákregiszter adatbázisával: Egy adat-összekapcsolás tanulságai. (2022) ORVOSI HETILAP 0030-6002 1788-6120 163 37 1481-1489
Gil-Sierra MD et al. Uso compasivo de durvalumab en cáncer de pulmón no microcítico: resultados en vida real. (2021) Revista de la OFIL ILAPHAR 1699-714X 31 2 196-200
Shen Cheng et al. Relationship Among Three Different Viruses and Primary Lung Cancer. (2021) INDIAN JOURNAL OF SURGERY 0972-2068 0973-9793 83 1 230-236
Li K. et al. M6A associated TSUC7 inhibition contributed to Erlotinib resistance in lung adenocarcinoma through a notch signaling activation dependent way. (2021) JOURNAL OF EXPERIMENTAL AND CLINICAL CANCER RESEARCH 0392-9078 1756-9966 40 1
Guo Yongjian et al. FV-429 enhances the efficacy of paclitaxel in NSCLC by reprogramming HIF-1 alpha-modulated FattyAcid metabolism. (2021) CHEMICO-BIOLOGICAL INTERACTIONS 0009-2797 1872-7786 350
Deng Yujiao et al. Epidemiological trends of tracheal, bronchus, and lung cancer at the global, regional, and national levels: a population-based study. (2020) JOURNAL OF HEMATOLOGY & ONCOLOGY 1756-8722 1756-8722 13 1
Agócs László et al. A tüdőrák sebészi kezelése, van új a nap alatt? [What's new in the surgical treatment of lung cancer?]. (2020) MAGYAR ONKOLÓGIA 0025-0244 2060-0399 64 3 190-195
Németh Bertalan et al. Cost-utility analysis of cariprazine compared to risperidone among patients with negative symptoms of schizophrenia. (2019) HEALTH POLICY AND TECHNOLOGY 2211-8837 8 1 84-91,
30522289
Szakcikk (Folyóiratcikk) | Tudományos[30522289]
Kearns Benjamin et al. The Incidence and Costs of Adverse Events Associated with Antidepressants: Results from a Systematic Review, Network Meta-Analysis and Multi-Country Economic Model. (2022) NEUROPSYCHIATRIC DISEASE AND TREATMENT 1176-6328 1178-2021 18 1133-1143
Bruhn David et al. The burden of illness for patients with schizophrenia and primary negative symptoms: A systematic literature review.. (2022) SCHIZOPHRENIA RESEARCH 0920-9964 1573-2509 248 341-344
Kearns Benjamin et al. Schizophrenia Treatment with Second-Generation Antipsychotics: A Multi-Country Comparison of the Costs of Cardiovascular and Metabolic Adverse Events and Weight Gain. (2021) NEUROPSYCHIATRIC DISEASE AND TREATMENT 1176-6328 1178-2021 17 125-137
Wang L. et al. A Systematic Review of Methods and Study Quality of Economic Evaluations for the Treatment of Schizophrenia. (2021) FRONTIERS IN PUBLIC HEALTH 2296-2565 9
Jin Huajie et al. A Systematic Review of Economic Models Across the Entire Schizophrenia Pathway. (2020) PHARMACOECONOMICS 1170-7690 1179-2027 38 6 537-555
Redekop W. Ken. How can we make better decisions about the development and implementation of health technologies?. (2019) HEALTH POLICY AND TECHNOLOGY 2211-8837 8 1 3-4
Szilberhorn László et al. Cost-effectiveness of introducing licensed GP practices to manage diabetes patients in Hungary. (2019) PRIMARY CARE DIABETES 1751-9918 1878-0210 13 5 462-467,
30613744
Szakcikk (Folyóiratcikk) | Tudományos[30613744]
Zhao W. et al. The feasibility and efficacy of a community-based multifactorial intervention to improve the cardiovascular risk factor control among patients with type 2 diabetes: A 2-year cluster randomized trial. (2022) MEDICINE 0025-7974 1536-5964 101 51